JAMA Acceptance Rate

Both journals accept roughly 5% of submissions, but their editorial focuses differ in ways that affect which papers belong where.

JAMA is particularly strong in:

• Health policy and public health: Studies with population-level significance, health system analyses, insurance coverage effects
• Preventive medicine: Screening, risk factor interventions, prevention trials
• Clinical epidemiology: Large observational studies with causal inference methods
• Health disparities: Studies examining equity, access, and outcomes across populations
• US health system research: Studies primarily relevant to US clinical practice and policy

NEJM is the better target for:

• Landmark randomized trials with hard endpoints (mortality, major cardiovascular events)
• Findings that would change first-line treatment guidelines
• International trials where global practice implications are the primary hook

The practical distinction: if your clinical trial has strong public health implications or addresses a US health policy question, JAMA may actually be a better fit than NEJM even if the science is comparable. Know which journal's scope aligns with your paper's primary message.

The desk rejection rate at JAMA (~80%) is lower than NEJM's (90%+), partly because JAMA's scope is somewhat broader and its readership includes more primary care physicians alongside specialists.

Papers that clear JAMA's desk typically:

• Report on a clinical question relevant to a large patient population
• Use a strong study design , ideally randomized, or large prospective cohort with good confounding control
• Have clinically meaningful effect sizes, not just statistical significance
• Frame findings in terms of patient care implications, not just statistical associations
• Are formatted correctly (JAMA has specific formatting requirements that must be followed)

What gets rejected at the desk:

• Papers primarily relevant to a narrow subspecialty (those belong in JAMA specialty journals or field-specific journals)
• Retrospective single-center studies without a compelling novelty argument
• Studies with surrogate endpoints where hard clinical outcomes data is feasible
• Papers that frame clinical findings as health policy commentary without the underlying study data

JAMA Network publishes specialty journals that may be more appropriate targets depending on your paper:

JAMA's IF has grown steadily over the past decade as clinical research publishing has consolidated around flagship general medical journals. The 2024 JCR IF is 55.0, up from 47.7 in 2020 and 39.0 in 2018. The 2024 IF of 55.0 is up from 51.0 in 2023, reflecting continued growth in citation density as JAMA's global clinical readership expands.

Note: 2021-2022 IFs were temporarily elevated due to COVID-19-related citation surges. The 2024 IF of 55.0 represents normalized post-pandemic levels. CiteScore and H-index from Scopus.

A cardiology paper with large clinical impact might belong in JAMA Cardiology rather than JAMA itself. A psychiatry trial goes to JAMA Psychiatry. Submit to the flagship only when the paper's implications genuinely cross subspecialty lines or have broad public health significance.

The question isn't "is 5% good enough to justify the submission time?" , the submission process takes a few hours. The question is whether a desk rejection in 1-2 weeks is the most likely outcome and whether you've chosen the right journal before investing that time.

For most well-executed clinical studies, JAMA is an aspirational but reachable target if the clinical and public health significance is clear. For studies that are methodologically strong but primarily of subspecialty interest, a JAMA specialty journal or Annals of Internal Medicine is a more realistic first submission.

If you need a fast decision, use this rule: choose the option that gives the clearest next action within two weeks. In journal strategy, clarity beats optionality. A clear journal fit with a realistic acceptance path is more valuable than chasing a prestige target that predictably desk-rejects your study.

This doesn't mean aiming low. It means matching manuscript type, audience, and significance level honestly, then moving quickly.

Pick one target journal and make a single-page submission brief: study question, primary result, target reader, and one-sentence significance claim. If that brief feels vague, the manuscript framing still needs work before submission.

This short exercise exposes scope mismatches early and reduces avoidable desk rejections.

One practical benchmark: if your abstract can't state patient population, intervention, comparator, and primary endpoint in four clean lines, the framing is still too vague for JAMA-level editorial screening.

JAMA Network Open is the open-access journal in the JAMA Network and accepts a substantially wider range of clinical research than JAMA itself. It carries a meaningful JCR score and strong indexing. Authors who need open-access publication and want the JAMA Network brand often find JNO the practical target.

Key differences from JAMA:

• Open access (APC required, currently around $3,000)
• Higher acceptance rate than JAMA itself
• Broader scope: accepts studies that are strong but not flagship-level
• Still indexed in PubMed, still peer-reviewed, still has meaningful IF

For researchers whose institution has a JAMA Network agreement covering APCs, JNO is worth evaluating as a primary target for solid clinical studies that don't meet JAMA's flagship significance bar.

JAMA requires all manuscripts to include effect sizes with confidence intervals, not p-values alone. The journal's statistical reporting policy is explicit: "Reporting of results should include effect sizes with 95% confidence intervals."

For clinical trials, this means hazard ratios with CI for survival outcomes, risk ratios or risk differences with CI for binary outcomes, and mean differences with CI for continuous outcomes. P-values alone are insufficient.

For observational studies, report odds ratios with CI from multivariable models, and describe the variables included in adjustment. Unadjusted associations without multivariable modeling are typically insufficient for JAMA-level clinical epidemiology.

Address these requirements in the methods section proactively. Statistical completeness is something JAMA's own statisticians review, and papers with incomplete statistical reporting receive revision requests on this point almost universally.

In our pre-submission review work evaluating manuscripts targeting JAMA, three patterns generate the most consistent desk rejections. Each maps directly to what JAMA's own author guidelines and published editorial commentary say they are screening for.

Subspecialty framing without broad physician significance. JAMA's submission guidelines require that accepted papers have "importance to a broad readership of physicians and health professionals." The failure pattern is a manuscript whose abstract and key points address a clinical question only subspecialists would recognize as important. A rigorous RCT in a rare autoimmune condition requires the same significance argument as any other paper: why does this matter to a general internist or primary care physician reading JAMA? Papers that skip this framing step are returned at the desk even with clean methodology, because the editors cannot assign reviewers who can validate the clinical importance beyond the narrow specialty.

Clinical findings that are statistically significant but not practice-changing. JAMA uses the Key Points format (Question/Findings/Meaning, maximum 100 words), and the Meaning field must state what clinicians should do differently after reading this paper. Papers where the Meaning reads "further research is needed" or describes an incremental refinement rather than a practice-level change get desk-rejected. JAMA's IF and reputation depend on publishing studies that alter what practicing physicians do with their next patient. An absolute risk reduction of 1-2% on a surrogate endpoint is not a practice-changing finding, regardless of statistical power.

Missing or incomplete EQUATOR checklist submissions. JAMA requires a completed EQUATOR reporting guideline checklist with every submission: CONSORT for RCTs, STROBE for observational studies, PRISMA for systematic reviews and meta-analyses. These are not optional supplements but mandatory submission items. Papers arriving without the appropriate checklist, or with checklist items marked "not applicable" without explanation, are returned before any editorial review. The author guidelines are explicit: "Manuscripts submitted without these completed checklists will be returned to authors prior to peer review." Running through the appropriate checklist before submission and addressing any incomplete items is the single most preventable administrative rejection cause at JAMA. A JAMA EQUATOR checklist and framing check can identify checklist gaps and framing issues before the submission window.